2011³â Ãá°è ´ëÇÑÀÓ»óÅ»¸ðÇÐȸ °³ÃÖ¿¡ ÁîÀ½ÇÏ¿© ¾È³çÇϽʴϱî? 2010³â 10¿ùºÎÅÍ ´ëÀü,¼¿ï,ºÎ»ê¿¡¼ ÀÓ»óÅ»¸ðÇÐȸ¼¼¹Ì³ª°¡ ¿·ÈÀ¸¸ç.¸¶Ä§³» 2011³â Ãá°èÇмú´ëȸ°¡ ¿¸®°Ô µÇ¾ú½À´Ï´Ù. »ç½Ç ¿ì¸®³ª¶óÁúº´ÀÇ ÃÖ°íºóµµ(Àα¸ÀÇ 20%:1õ¸¸)ÀÎ Å»¸ðÁõ, ´Ù¸¥ÀÇÇÐÀº ±Þ¼ÓÈ÷ ¹ßÀüÇßÁö¸¸ ÇöÀç Å»¸ðÄ¡·á´Â ¾Æ½Ã´Ù½ÃÇÇ °ÉÀ½¸¶¼öÁØÀÔ´Ï´Ù. Hair FollicleÀº Bone Marrow³ª Tumor Cell¸¸Å metabolismÀÌ ºü¸£°í ÁÖÀ§ÀÇ ¸ðµç¿äÀο¡ °¡Àå sensitive ÇÕ´Ï´Ù. Å»¸ðÀÇÇб³À°°úÁ¤,Å»¸ð±³°ú¼,Å»¸ð³í¹®µµ °ÅÀÇ ¾øÀ¸¸ç Ä¡·á¿¡ ´ëÇÑ ¿øÄ¢°ú ±âÁصµ ¾øÀÌ °æÇèÀÇÇÐÀû Ãø¸é Áï ³²¼ºÈ£¸£¸ó ¾ïÁ¦Á¦,µÎÇǸÞÁ¶¼¼¶óÇÇ,topical minoxidilÁ¦Á¦¿¡ °ÅÀÇ ÀÇÁ¸Çϴµí ÇÕ´Ï´Ù. Å»¸ð°¡ ÀÌÁ¤µµ·Î ÇØ°áµÈ´Ù¸é ¾ó¸¶³ª ÁÁ°Ù½À´Ï±î? ¾Æ½Ã´Ù½ÃÇÇ ÀÇÇÐÀº evidenceÀ§ÁÖÀÇ ÃÖ°íÀÇ °úÇÐÀÔ´Ï´Ù. Å»¸ðÄ¡·á´Â º¹ÀâÇÑ ¿ì¸®¸öÀÇ Á¾ÇÕÆÇÀÔ´Ï´Ù. Å»¸ð´Â medical conditionÀÇ ÇϳªÀÇ symptomÀÔ´Ï´Ù. ÀÌ medical conditionÀ» ÇØ°áÇØ¾ß ºñ·Î¼Ò Å»¸ð°¡ ÇØ°áµÇ´Â °ÍÀÔ´Ï´Ù. ´Ü¼ø µÎÇÇ¿¡¼ÀÇ °ü¸®¿Í Ä¡·á´Â Ä¡·áµ¿¾È ÀϽÃÀûÀ¸·Î ¸ð¹ßÀ» ±½°ÔÇÒ »ÓÀÔ´Ï´Ù. ÀÇ»çÀÇ Àü¹®Ä¡·á´Â °¡´Ã¾îÁø ¸ð¹ßÀ» ±½°Ô ÇÏ¸é¼ miniaturizedµÈ ¸ð¹ßÀÌ ºüÁö°í ³ µÚ Áï kenogen»óÅÂÀÇ À§ÃàµÈ hair follicleÀÌ »¡¸® ¿Ã¶ó¿Í °Ç°ÇÑ hair cycleÀ» ¹âÀ» ¼ö ÀÖµµ·Ï ÇØ¾ßÇÕ´Ï´Ù. ¿¹¸¦ µé¾î Hypothalamic-Pituitary-Adrenal,Gonadal,Thyroid Axis´Â Brain-Hair Follicle Axis¿¡µµ ¶È°°ÀÌ ÀÛ¿ëÇÕ´Ï´Ù.±×¸¸Å º¹ÀâÇÏ´Ù´Â »ç½ÇÀÔ´Ï´Ù.±×¸®°í ³²¼ºÇüÅ»¸ð´Â Á¤½ÅÀûÀÎ ¹®Á¦¿Ü¿¡µµ ¿äÁîÀ½ ±ÞÁõÇϰí ÀÖ´Â coronary heart disease,prostate cancer¸¦ Á¤»óÀκ¸´Ù ÈξÀ ¸¹ÀÌ µ¿¹ÝÇϰí ÀÖÀ¸¸ç ±× ¿Ü Àν¶¸°ÀúÇ×¼º,°íÇ÷¾Ð,°íÁöÇ÷Áõ,´Ù³¶¼º³¼ÒÁõÈıº,´ç´¢µîµµ ºóµµ°¡ ³ô½À´Ï´Ù. ±×¸®°í ¼ö¸¹Àº ¾ÏȯÀÚÀÇ ÈÇпä¹ýÀ̳ª ¹æ»ç¼±Ä¡·áÈÄ ¿À´Â Å»¸ðÀÇ ºü¸¥Ä¡·á´Â ȯÀÚ¿¡°Ô ¾Ï¿¹ÈÄ¿¡ µµ¿òÀ» ÁÖ°í Å»¸ðȯÀÚ(ƯÈ÷ ¿©¼º¿¡¼)ÀÇ ÀÚÁ¸½ÉÀ» »ì¸®´Â ±æÀÔ´Ï´Ù .±×¸®°í º¸¸é ¾ÏÀü¹®º´¿ø¿¡¼ ¾ÏȯÀÚÀÇ Å»¸ð¿¡ ´ëÇØ ¾ó¸¶³ª ¹«°ü½ÉÇÏ°í ¹«ÁöÇÏ´Ù´Â °ÍÀ» ¾Ë ¼ö ÀÖ½À´Ï´Ù. ±×¸®°í ¿äÁîÀ½ Å©°Ô Áõ°¡Çϰí ÀÖ´Â ¼Ò¾Æ & û¼Ò³â Å»¸ðÄ¡·áµµ °ÅÀÇ ¼ÕÀ» ³õ°í ÀÖ´Â »óÅÂÀÔ´Ï´Ù. Å»¸ð´Â ±âÃÊÀÇÇÐó·³ ±Ùº»À» ÃæºÐÈ÷ °øºÎ & ¿¬±¸ÇÏ°í³ µÚ Â÷±ÙÂ÷±Ù Ç®¾î³ª°¡¾ß ȯÀÚÀÇ Àüü ¸öµµ ÁÁ¾ÆÁö¸é¼ ÇØ°áµÉ ¼ö ÀÖ½À´Ï´Ù, ÀÌ·± °úÁ¤À» °£°úÇÏ°í »¡¸® »¡¸® Ä¡·á¹ý(ƯÈ÷ µÎÇÇÄ¡·á)¿¡¸¸ ¸Å´Þ¸®´Â °ÍÀº »ç»ó´©°¢ÀÏ »ÓÀÔ´Ï´Ù.Å»¸ð´Â ´Ù¾çÇÑ ¿øÀÎÀÌ ÀÖ°í ȯÀÚ¸¶´Ù Ä¡·á°¡ ´Ù¸£±â ¶§¹®¿¡ ÀϹÝÇǺÎÄ¡·á³ª ¼ºÇü¼ö¼úó·³ tipÀÌ ÀÖÀ» ¼ö ¾ø½À´Ï´Ù. À̹ø Ãá°è ´ëÇÑÀÓ»óÅ»¸ðÇÐȸ Çмú´ëȸ¿¡¼´Â ´Ü ÇÏ·ç·Î´Â Á¤¸» ºÎÁ·ÇÑ ½Ã°£ÀÌÁö¸¸ Å»¸ðÄ¡·á¿¡ ´ëÇÑ ¹æÇâÀ» ¿Ã¹Ù¸£°Ô Àâ¾Æ ´ëÇѹα¹ Å»¸ðÇйßÀü°ú Å»¸ðȯÀÚÀÇ °íÅëÀÌ ÇÏ·ç »¡¸® ÇØ°áµÇ±â¸¦ ¹Ù¶ø´Ï´Ù. ´ëÇÑÀÓ»óÅ»¸ðÇÐȸ ȸÀå À̱âÁö # ÀϽÃ:2011³â 3¿ù 13ÀÏ(ÀÏ¿äÀÏ) # Àå¼Ò:¼¿ï ¹é¹ü±â³ä°ü Á¦2±³À°°ü # ÁÖÃÖ:´ëÇÑÀÓ»óÅ»¸ðÇÐȸ # µî·Ï:22¸¸¿ø(°³¿øÀÇ),18¸¸¿ø(Àü°øÀÇ,°øº¸ÀÇ,±ºÀǰü),25¸¸¿ø(ÇöÀåµî·Ï),30¸¸¿ø(ÇÑÀÇ»ç,¹Ì¿ë±³¼ö,1±Þ¸ð¹ß°ü¸®»ç) # ÀԱݰèÁÂ:ÇϳªÀºÇà 320-8100-01-18908 Á¤Àμ÷(016-510-4014) # E-mail: hairloss @ hanmail.net À̸§,º´¿øÀüȹøÈ£,¸éÇã¹øÈ£,ÈÞ´ëÆù¹øÈ£,E-mail¸¦ ²À º¸³»Áֽðí "´ëÇÑÀÓ»óÅ»¸ðÇÐȸ"·Î ¸í±âÇØÁֱ⠹ٶø´Ï´Ù. *Àü°øÀÇ,°øº¸ÀÇ,±ºÀǰü, ÇÑÀÇ»ç,¹Ì¿ë±³¼ö,1±Þ ¸ð¹ß°ü¸®»çµµ ¸í±âÇØÁÖ±â¹Ù¶ø´Ï´Ù #µî·ÏÈÄ ÀüÈ(019-528-4014)³ª ¹®ÀÚ(019-528-4014)¸¦ ²ÀÇØÁֱ⠹ٶø´Ï´Ù.(¿¬¶ôó) **ÃÖ±Ù ¿Ü±¹¿¡¼ Å»¸ð¿¡ ´ëÇØ ¾ð·Ð¿¡ ¹ßÇ¥µÇ°í ÀÖ´Â ÇÖÀÕ½´°¡ ¹Ø¿¡ ÀÖ´Â °Àdz»¿ë¿¡ ´Ù Æ÷ÇԵǾî ÀÕ½À´Ï´Ù.(Lhx2 gene,¸ð¹ß ÁÙ±âÁ¶»ó¼¼Æ÷, astressin, ¸ð¹ß Áٱ⼼Æ÷Áõ½Ä¿ä¹ýµî) À̹ø °ÀÇ´Â ÀúÀÚ Á÷Á¢°ÀÇ·Î Æò¼Ò ½±°Ô µéÀ» ¼ö ¾ø´Â Å»¸ð°ÀÇÀÓÀ» È®½ÅÇÕ´Ï´Ù. #´ëÇÑÀÓ»óÅ»¸ðÇÐȸ ȸÀå (À̱âÁö) Àú¼ ¹× ³í¹® 1.Dr. Lee »ý¾ó ÇǺΠ¹ÌÀÎ ÇÁ·ÎÁ§Æ®(2008³â) 2.ÃÖ½ÅÅ»¸ðÁõÀÇ Áø´Ü°ú Ä¡·á(2009³â,380ÆäÀÌÁö,ÀÇ»çÀü¹®¿ë) 3.ÃÖ½ÅÅ»¸ðÁõÀÇ °ü¸®¿Í Ä¡·á(2009³â,220ÆäÀÌÁö,ÀϹÝÀοë) 4.Easy Alopecia(2010³â,95ÆäÀÌÁö,ÀϹÝÀοë) 5.Alopecia(2010³â 7¿ùÃâ°£,1020ÆäÀÌÁö,ÀÇ»çÀü¹®¿ë) 6.Best Alopecia(2010³â 11¿ùÃâ°£.800ÆäÀÌÁö,ÀÇ»çÀü¹®¿ë) 7.All of Alopecia(2011³â 3¿ùÃâ°£¿¹Á¤,»óÁßÇϱÇ,3450ÆäÀÌÁö,ÀÇ»çÀü¹®¿ë) 8.³í¹®: The Effect of combination treatment in Male & Female Androgenetic Alopecia (2010³â 7¿ùÈ£ ºÎ»êÀÇ»çȸÁö ¹× ´ëÇÑÀÇ»çÇùȸÁö ¹ßÇ¥) 9.³í¹®: Treatment of Female Pattern Hair Loss in association with adrenal fatigue (2010³â 12¿ù & 2011³â 1¿ùÈ£ ºÎ»êÀÇ»çȸÁö ¹ßÇ¥) 10.³í¹®: Treatment of Adolescent Androgenetic Alopecia (2011³â 3¿ù ¹ßÇ¥¿¹Á¤) 11.³í¹®:Treatment of Postmenopausal Female Pattern Hair Loss with antiandrogen drug (2011³â 7¿ù ¹ßÇ¥¿¹Á¤) #Å»¸ð´Â °í°¡ÀÇ ÀÇ·á±â°èµµ ÇÊ¿ä¾ø°í Å«ÅõÀÚ°¡ ÇÊ¿ä¾øÀ¸¸ç ÀÇ»çÀÚ½ÅÀÇ Å»¸ð¿¡ ´ëÇÑ °íÀ¯ÀÇ ±¤¹üÀ§ÇÏ°Ô Ç³ºÎÇÏ°í ´Ù¾çÇÑ ÀÇÇÐÁö½ÄÀÌ ÇÊ¿äÇÏ¸ç ³ªÀ̱⠵é¾îµµ ¼ºÇü¼ö¼ú°ú °°ÀÌ ÇÕº´Áõ¿¡ ´ëÇÑ ¿°·Á¾øÀÌ ÇÒ ¼ö ÀÖÀ¸¸ç µ¿½Ã¿¡ Å»¸ð¿Í °ü·ÃµÈ ¸öÀÇ ´Ù¸¥°÷À» ±¤¹üÀ§ÇÏ°Ô Ä¡·áÇØ°¥½Ã ÀÎÁ¤¹Þ´Â À¯´ÉÇÑ Àǻ簡 µÉ ¼ö ÀÖÀ¾´Ï´Ù.. # Àå¼Ò¿Í ½Ã°£Àº Ư¼öÇÑ °æ¿ì º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù. °ÀÇÀÏÁ¤ 1.¿ÀÀü8:50ºÐ-9:10ºÐ: Á¢¼ö¹× µî·Ï 2.¿ÀÀü 9½Ã 10ºÐ-9½Ã 50ºÐ 1.The Human Skin as Hormone Target 2.Disease of civilization: Hair Loss 3.¿ÀÀü 10½Ã-10½Ã 50ºÐ 1.The control of hair growth 2.Molecular mediators of Hair FollicleI2010³â NatureÁö ¹ßÇ¥³í¹®) 3.A Human Folliculoid Microsphere Assay for exploring Epithelial–Mesenchymal interactions in the Human Hair Follicle 4.Endogeneous substances that affect hair growth(bFGF,PDGF,TGF-B,IL-1,FGF-5, EGF,KGF,IGF-1,Substance P,PTH, etc) 4.¿ÀÀü 11½Ã-11½Ã 50ºÐ 1.Schematic representation of hair follicle morphogenesis and subsquent first hair cycle 2.Controls of Hair Follicle Cycling 3.The Hair Cycle or(to put it another way) Why is hair growth cyclical? 4.Apoptosis in the Hair Follicle 5.An Investigation of Apoptosis in Androgenetic Alopecia 6.Identification of hair cycle-associated genes from time-course gene expressiom. 7.N-WASP is a novel regulator of hair follicle cycling that controls antiproliferative TGF-B pathways(2010³â Science ¹ßÇ¥³í¹®) 8.Hair Follicle Stem cell in the hair growth cycle 5.¿ÀÀü 12½Ã-12½Ã 50ºÐ 1.Pathogenesis of Androgenetic Alopecia 2,Gene and Androgenetic Alopecia 3.The HairDX genetic test for Pattern Hair Loss(AGA) 6.¿ÀÈÄ12½Ã 50ºÐ-¿ÀÈÄ2½Ã Á¡½É½Ã°£(Lunch Time) 7.¿ÀÈÄ2½Ã-2½Ã 50ºÐ 1.Testosterone and Hair Loss a.What is the role of the androgens and sex hormone binding globulin(SHBG)? b.Peripheral Conversion and Metabolism c.The relationship between Insulin and Testosterone d.Adrenal androgen regulation and physiology 2.The Hair Follicle as an Estrogen Target and Source 3.Androgenetic alopecia and insulin resistance in young men 4.Premature androgenic alopecia and insulin resistance. Male equivalent of polycystic ovary syndrome 5.Cortisol, Immunostimulation and Male Pattern Baldness 5.Thyroid hormones directly alter human hair follicle function: anagen prolongation and stimulation of both hair matrix 6.Prolactin and its receptor are expressed in hair follicle epithelium show hair cycle-dependent expression and induce catagen 7.Human Hair Follicles are an extrarenal source and nonhematopoietic target of erythropoietin. 8.¿ÀÈÄ 3½Ã-3½Ã50ºÐ 1.Energy,Nutrition and Androgenetic Alopecia 2.Stress and the Underestimated Psychosocial Impact of Telogen Effluvium and Androgenetic Alopecia 3.Stress Inhibits Hair Growth by Induction of Premature Catagen Development and Deleterious Perifollicular Inflammatory Events via Substance P-Dependent Pathways 4.Neurogenic Inflammation in stress-induced termination of Hair growth is promoted by Nerve Stimulation Factor. 5.Circulation and Androgenetic Alopecia a,Active Hair Growth(Anagen) is associated with Angiogenesis. b.Control of Hair Growth and Follicle size by VEGF-mediated angiogenesis c.Association of androgenetic alopecia and hypertension d,Male Pattern Baldness and Coronary Heart Disease 6.Association of Androgenetic Alopecia with Metabolic syndrome with men 7.Detoxification and Androgenetic Alopecia 8.Profiling the response of the Human Hair follicle to the Ultraviolet Radiation 9.¿ÀÈÄ 4½Ã-4½Ã50ºÐ Hair Follicle Stem cell 1.Long-term renewal of hair follicles from clonogenic multipotent stem cells 2.Telogen-anagen transition showing hair follicle stem cells forming nascent hair follicle 3.Human bulge cell morphology and markers. 4.Melanocyte stem cells in the hair follicle unit 5.Chemotheraphy targets Hair Follicle vascular network but not stem cell. 6.Female Pattern Hair Loss 7.Treatment of postmenopausal Female Pattern Hair Loss with antiandrogen drug 8.Treatment of Pediatric and Child hair loss 9. Treatment of Adolescent Androgenetic Alopecia 10.¿ÀÈÄ 5½Ã-5½Ã50ºÐ Androgenetic AlopeciaÀÇ Áø´Ü°ú Ä¡·á |